Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal

References

• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol 2015;3:193–200
   Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–78
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684–92
   PubMed Web of Science ®Google Scholar
• L’Hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185–201
   PubMed Web of Science ®Google Scholar
• L’Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric 2013;16(Suppl 1):44–53
   PubMed Web of Science ®Google Scholar
• WHI Writing Group. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• L’Hermite M. Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use. Climacteric 2017 Feb 9. Epub ahead of print. DOI: 10.1080/13697137.2017.1285277
   Web of Science ®Google Scholar
• Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol 2014;142:16–29
   PubMed Web of Science ®Google Scholar
• Nachtigall LE, Raju U, Banerjee S, Wan L, Levitz M. Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels. Menopause 2000;7:243–50
   PubMed Web of Science ®Google Scholar
• Zhang F, Chen Y, Pisha E, et al. The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem Res Toxicol 1999;12:204–13
   PubMed Web of Science ®Google Scholar
• Jayachandran M, Mukherjee R, Steinkamp T, et al. Differential effects of 17 beta-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am J Physiol Circ Physiol 2005;288:H2355–62
   PubMed Web of Science ®Google Scholar
• Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. Br Med J 2008;337:a386
   PubMed Web of Science ®Google Scholar
• Racine A, Bijon A, Fournier A, et al. Is transdermal menopausal hormone therapy a safer option than oral therapy? Can Med Assoc J 2013;185:549–50
   Web of Science ®Google Scholar
• Lobo RA. What is the effect of estrogen on blood pressure after menopause? Menopause 2006;13:331–3
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas 2004;49:189–203
   PubMed Web of Science ®Google Scholar
• Steiner AZ, Hodis HN, Lobo RA, Shoupe D, Xiang M, Mack WJ. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the estrogen in the prevention of atherosclerosis trial. Menopause 2005;12:728–33
   PubMed Web of Science ®Google Scholar
• Li C, Engstrom G, Hedblad B, Berglund G, Janzon L. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke 2005;36:725–30
   PubMed Web of Science ®Google Scholar
• Løkkegaard E, Jovanovic Z, Heitmann B, et al. Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study. Arch Neurol 2003;60:1379–84
   PubMed Web of Science ®Google Scholar
• Shufelt CL, Merz CNB, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative observational study. Menopause 2014;21:260–6
   PubMed Web of Science ®Google Scholar
• Blondon M, van Hylckama Vlieg A, et al. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers. J Thromb Haemost 2014;12:879–86
   PubMed Web of Science ®Google Scholar
• Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost 2010;8:1736–44
   PubMed Web of Science ®Google Scholar
• Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA 2014;174:25–31
   Google Scholar
• Savolainen-Peltonen H, Tuomikoski P, Korhonen P, et al. Cardiac death risk in relation to the age at initiation or the progestin component of hormone therapies. J Clin Endocrinol Metab 2016;101:2794–801
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Br Med J 2012;345:e6409
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31
   PubMed Web of Science ®Google Scholar
• Rylance P, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. Br Med J (Clin Res Ed) 1985;290:13–14
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke. Impact of the route of estrogen administration and type of progestogen. Stroke 2016;47:1734–41
   PubMed Web of Science ®Google Scholar
• Canonico M, Scarabin P-Y. Oral versus transdermal estrogens and venous thromboembolism in postmenopausal women: what is new since 2003? Menopause 2016;23:587–8
   PubMed Web of Science ®Google Scholar
• Caufriez A, Leproult R, L’Hermite-Balériaux M, Kerkhofs M, Copinschi G. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab 2011;96:E614–23
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC. The estrogen paradox. Nat Clin Pract Endocrinol Metab 2007;3:496–7
   PubMedGoogle Scholar
• Mueck AO, Seeger H. Estrogen as a new option for prevention and treatment of breast cancer: does this need a ‘time gap’? Climacteric 2015;18:444–7
   PubMed Web of Science ®Google Scholar
• de Villiers T, Hall JE, Pinkerton J, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016;19:313–15
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014;145:535–43
   PubMed Web of Science ®Google Scholar
• Jones ME, Schoemaker MJ, Wright L, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Br J Cancer 2016;115:607–15
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. Menopause 2016;23:1199–203
   PubMed Web of Science ®Google Scholar
• Courtin A, Communal L, Vilasco M, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 2012;131:49–63
   PubMed Web of Science ®Google Scholar
• Murkes D, Conner P, Leifland K, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188–91
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault M-C, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138–43
   PubMed Web of Science ®Google Scholar
• Løkkegaard E, Andreasen A, Jacobsen R, Nielsen L, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660–8
   PubMed Web of Science ®Google Scholar
• Simon JA, Laliberté F, Duh MS, et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause 2016;23:600–10
   PubMed Web of Science ®Google Scholar
• Scarabin P-Y, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolic risk. Lancet 2003;362:428–32
   PubMed Web of Science ®Google Scholar
• Simon JA. What if the Women’s Health Initiative had used transdermal estradiol and oral progesterone instead? Menopause 2014;21:769–83
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas 2015;82:303–6
   Web of Science ®Google Scholar
• Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008;29:2031–41
   PubMed Web of Science ®Google Scholar
• Lobo RA, Clarkson TB. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 2011;18:237–40
   PubMed Web of Science ®Google Scholar
• Lewandowski KC, Komorowski J, Mikhalidis DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006;91:3123–30
   PubMed Web of Science ®Google Scholar
• Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006;189:436–42
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer M, Rexrode K. Postmenopausal hormone therapy. Role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861–6
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729–38
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women’s Health Initiative randomized trial. J Bone Miner Res 2006;21:817–28
   PubMed Web of Science ®Google Scholar
• Shulman LP. Transdermal hormone therapy and bone health. Clin Interv Aging 2008;3:51–4
   PubMed Web of Science ®Google Scholar
• Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443–51
   PubMed Web of Science ®Google Scholar
• Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 2012;19:109–17
   PubMed Web of Science ®Google Scholar
• Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2015;18:121–34
   PubMed Web of Science ®Google Scholar
• Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014;124:1147–56
   PubMed Web of Science ®Google Scholar
• Tourgeman DE, Boostanfar R, Chang L, Lu J, Stanczyk FZ, Paulson RJ. Is there evidence for preferential delivery of ovarian estradiol to the endometrium? Fertil Steril 2001;75:1156–8
   PubMed Web of Science ®Google Scholar
• Mørch LS, Kjær SK, Keiding N, Løkkegaard E, Lidegaard Ø. The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study. Int J Cancer 2016;138:1506–15
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Vaginal estradiol use and the risk for cardiovascular mortality. Hum Reprod 2016;31:804–9
   PubMed Web of Science ®Google Scholar
• Lethaby A, Ayeleke R, Roberts H. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016;8:CD001500
   Google Scholar
• Rioux JE, Devlin MC, Gelfand MM, Steinberg WM, Hepburn DS. 17[beta]-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156–61
   PubMed Web of Science ®Google Scholar
• Griesser H, Skonietzki S, Fischer T, Fielder K, Suesskind M. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012;71:360–8
   PubMed Web of Science ®Google Scholar
• Delgado JL, Estevez J, Radicioni M, Loprete L, del Prado JM, Magro CN. Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. Climacteric 2016;19:172–80
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Triratanachat S, Chaikittisilpa S, Grob P, Prasauskas V, Taechakraichana N. Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. Climacteric 2013;16:347–55
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation. Climacteric 2007;10:358–70
   PubMed Web of Science ®Google Scholar
• Cicinelli E, Schonauer LM, Galantino P, Matteo MG, Cassetta R, Pinto V. Mechanisms of uterine specificity of vaginal progesterone. Hum Reprod 2000;15(Suppl 1):159–65
   PubMed Web of Science ®Google Scholar
• Cicinelli E, de Ziegler D, Alfonso R, Nicoletti R, Bellavia M, Colafiglio G. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 2005;83:1859–63
   PubMed Web of Science ®Google Scholar
• Noé G, Sitruk-Ware R, Zegers-Hochschild F, et al. Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women. Climacteric 2010;13:433–41
   PubMed Web of Science ®Google Scholar
• Paulson RJ, Collins MG, Yankov VI. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab 2014;99:4241–9
   PubMed Web of Science ®Google Scholar
• Panjari M, Davis SR. DHEA for postmenopausal women: a review of the evidence. Maturitas 2010;66:172–9
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23:243–56
   PubMed Web of Science ®Google Scholar
• Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon J. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015;18:233–40
   PubMed Web of Science ®Google Scholar
• Fernandes T, Costa-Paiva LH, Pedro AO, Baccaro LFC, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy. A randomized controlled trial. Menopause 2016;23:792–8
   PubMed Web of Science ®Google Scholar
• Lobo RA, Davis SR, De Villiers TJ, et al. Prevention of diseases after menopause. Climacteric 2014;17:540–56
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pickar JH, Stevenson JC, Mack WJ, Hodis HN. Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis 2016;254:282–90
   PubMed Web of Science ®Google Scholar